Stockscreener 앱 받기
55.87
0.30%
0.064
Moderna Inc 주식(MRNA)의 최신 뉴스
Eversept Partners LP Has $8.11 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Renaissance Technologies LLC Acquires 312,800 Shares of Moderna, Inc. $MRNA - MarketBeat
(MRNA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Moderna (MRNA) Laps the Stock Market: Here's Why - Yahoo Finance Singapore
After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy? - The Globe and Mail
After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy? - The Motley Fool
Therapeutics Stocks Q1 Highlights: Moderna (NASDAQ:MRNA) - Yahoo Finance
Weiss Asset Management LP Has $4.76 Million Position in Moderna, Inc. $MRNA - MarketBeat
Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Moderna stock stays tied to vaccine demand and cash burn - Ad-hoc-news.de
Moderna, Inc. Revenue Breakdown – BX:0QF - TradingView
Moderna Inc (MRNA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Moderna: A Stock to Watch or a Risky Bet? - The Globe and Mail
Moderna Inc (MRNA) Institutional Confidence - TradingKey
Moderna Inc (MRNA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Moderna, Inc. Revenue Breakdown – VIE:MRNA - TradingView
Moderna stock may move 4.2% on July 31 earnings release By Investing.com - Investing.com Nigeria
Moderna stock may move 4.2% on July 31 earnings release - Investing.com
Moderna Inc (MRNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Baillie Gifford (MRNA) discloses 18.2M Moderna shares in latest 13G/A - Stock Titan
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance Singapore
Moderna (MRNA) Stock Looks Above Fair Value After Cancer Trial News - simplywall.st
First Trust Advisors LP Raises Stock Position in Moderna, Inc. $MRNA - MarketBeat
GC Biopharma Files for Phase 2 Trial of Korean-Made mRNA COVID-19 Vaccine, Aiming for August Start - finance.biggo.com
Moderna Inc (MRNA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Moderna (MRNA) Projected to Post Earnings on Friday - MarketBeat
Earnings Preview: What To Expect From Moderna’s Report - Yahoo Finance
Biotech experts want FDA drug reviews based on science, not politics - marketscreener.com
Himension Capital Singapore PTE. LTD. Cuts Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Rabies Vaccine Candidate by Moderna Inc.mRNA approach in early trials - AD HOC NEWS
Bank of New York Mellon Corp Reduces Position in Moderna, Inc. $MRNA - MarketBeat
California Public Employees Retirement System Purchases 149,192 Shares of Moderna, Inc. $MRNA - MarketBeat
Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near? - Yahoo! Finance Canada
Moderna (MRNA) Appoints Michael McDonnell To Board As Committee Roles Shift - Yahoo Finance
The mRESV by Moderna. An mRNA RSV vaccine candidate for older adults - Ad-hoc-news.de
Moderna stock stabilizes as oncology pipeline and vaccine revenue reshape growth outlook - Ad-hoc-news.de
MRNA Maintained and Target Raised by Goldman Sachs -- Now $67.00 - GuruFocus
Moderna stock outlook: doubled YTD but Wall Street says the easy money is made - Investing.com
Moderna Inc. Stock Slides 3.8%, Underperforms Peers - webull.com
Moderna, Inc. $MRNA Stock Holdings Increased by Fifth Third Bancorp - MarketBeat
Moderna Hits CureVac With Countersuit In COVID Vax Fight - Law360
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback? - Yahoo Finance
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo! Finance Canada
Moderna, Inc.'s Stock Price Drops to $59.49, a Decline of 3.77%, Investors Eye Market Performance Closely - Smartkarma
Moderna says CureVac broke agreement by suing over COVID vaccine patents - Reuters
Moderna stock steadies as RSV and COVID vaccine revenues reshape outlook - AD HOC NEWS
Moderna counters CureVac patent lawsuit over Covid-19 vaccines By Investing.com - Investing.com Canada
Goldman Sachs Adjusts Moderna Price Target to $67 From $49, Maintains Neutral Rating - marketscreener.com
Wolfe Research raises Moderna stock price target to $25 on updates - Investing.com
D.A. Davidson & CO. Decreases Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Encyclopedia Britannica
Moderna stock edges higher as Spikevax sales stabilize and pipeline spending stays elevated - ad-hoc-news.de
The mRNA-1345 RSV vaccine candidateModerna Inc. bets on older adults - Ad-hoc-news.de
US Seeks Toss Of Arbutus Patent Suit Over Moderna Vaccine - Law360
Moderna stock trades lower as COVID vaccine demand weighs on 2026 outlook - ad-hoc-news.de
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
MRNA Advances Cancer Pipeline With New Immunotherapy Study - Yahoo Finance
Moderna stock trades steadily as mRNA pipeline and COVID revenues shape outlook - ad-hoc-news.de
Fed. Circ. Asked Not To Shift Moderna Vax Patent Case To Gov't - Law360
Form 4 Moderna Inc For: 16 July By Investing.com - Investing.com Nigeria
Moderna, Inc.’s Stock Price Plummets to $63.15, Marking a Significant 7.51% Decline - Smartkarma
Moderna president Stephen Hoge sells $3.6m in stock - Investing.com
Moderna, Inc. (MRNA) president exercises options and sells 53,336 shares under 10b5-1 plan - Stock Titan
Lobbying Update: $290,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? - Stocktwits
0.24%
0.61%
자본화:
|
볼륨(24시간):